Zepbound® (tirzepatide) KwikPen 10 mg/0.6 mL

Product Description: Zepbound® (tirzepatide) KwikPen 10 mg/0.6 mL

Zepbound® (tirzepatide) is a once-weekly injectable prescription medication indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management. The 10 mg/0.6 mL KwikPen is a multi-dose delivery system prescribed for patients who have successfully titrated through lower doses and require this strength to achieve or maintain their target weight loss goals.

Product Specifications

• Dosage Strength: 10 mg per 0.6 mL.

• Presentation: KwikPen (Multi-dose pre-filled delivery system).

• Indication: Chronic weight management in adults with an initial BMI of $\ge 30\text{ kg/m}^2$ (obesity) or $\ge 27\text{ kg/m}^2$ (overweight) with at least one weight-related comorbid condition.

• Administration: Subcutaneous injection once weekly in the abdomen, thigh, or upper arm.

• Mechanism of Action: A potent dual GIP and GLP-1 receptor agonist that regulates metabolic pathways, enhances satiety, and slows gastric emptying to effectively reduce caloric intake.

Important Safety Information

WARNING: RISK OF THYROID C-CELL TUMORS

In rodent models, tirzepatide has been shown to cause thyroid C-cell tumors. It is unknown whether Zepbound causes these tumors, including medullary thyroid carcinoma (MTC), in humans. Zepbound is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

Clinical Considerations

• Dose Escalation: At the 10 mg level, close monitoring for gastrointestinal adverse events (nausea, vomiting, diarrhea, abdominal pain) is essential. Patients should be assessed for clinical signs of dehydration or electrolyte imbalance.

• Device Handling: Patients must be educated on the use of the multi-dose KwikPen, including the necessity of attaching a new, sterile needle for every weekly injection and priming the pen prior to use.

• Contraindications: History of MTC/MEN 2; known serious hypersensitivity to tirzepatide or any product components.

• Hypoglycemia: Increased risk when used concomitantly with insulin or insulin secretagogues; clinicians should consider dose adjustments for concurrent diabetes medications.

Storage and Handling

• Before First Use: Store in the refrigerator at 36°F to 46°F (2°C to 8°C). Do not freeze.

• After First Use: The pen can be stored at room temperature (not exceeding 86°F or 30°C) for up to 30 days.

• Stability: Protect from direct light and excessive heat. Inspect the solution before each use; it should be clear and colorless to slightly yellow. Do not use if the solution appears cloudy or contains particulate matter.

Disclaimer: This information is provided for professional reference only and does not constitute medical advice, diagnosis, or treatment. Always refer to the official FDA-approved Prescribing Information, Medication Guide, and Instructions for Use for comprehensive clinical guidance.